tiprankstipranks
Advertisement
Advertisement
Alnylam price target lowered to $410 from $505 at Truist
PremiumThe FlyAlnylam price target lowered to $410 from $505 at Truist
14d ago
Alnylam price target raised to $400 from $370 at Morgan Stanley
Premium
The Fly
Alnylam price target raised to $400 from $370 at Morgan Stanley
18d ago
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
Premium
The Fly
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
18d ago
Komodo expands strategic partnership with Alnylam
PremiumThe FlyKomodo expands strategic partnership with Alnylam
1M ago
Alnylam: Neutral Stance Maintained as TTR-CM Growth Slows and Pipeline Remains Early; $370 Price Target Unchanged
Premium
Ratings
Alnylam: Neutral Stance Maintained as TTR-CM Growth Slows and Pipeline Remains Early; $370 Price Target Unchanged
1M ago
Analyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
Premium
Ratings
Analyst Reiterates Buy on Alnylam, Maintains $510 Price Target on Pipeline and Growth Optionality
1M ago
Alnylam, Inceptive form strategic AI collaboration
PremiumThe FlyAlnylam, Inceptive form strategic AI collaboration
2M ago
Analyst Reiterates Hold Rating and Keeps $370 Price Target Amid Mixed Near‑Term Amvuttra Trends
Premium
Ratings
Analyst Reiterates Hold Rating and Keeps $370 Price Target Amid Mixed Near‑Term Amvuttra Trends
2M ago
Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor
Premium
Company Announcements
Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100